Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PARTUM: Aspirin vs LMWH for Postpartum VTE Prevention
NCT06494878Phase 3Recruiting
- Sponsor
- University of Calgary
- Start
- Jun 2026
- Primary completion
- Sep 2030
- Modality
- Orthosteric Ligands
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial of aspirin in venous thromboembolism (VTE) (2 arms), sponsored by University of Calgary. Primary endpoint: Symptomatic Venous Thromboembolism at 6 weeks. Started Jun 2026; status: recruiting.
02
Drugs
aspirin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT06494878.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06494878.